奥美沙坦酯联合利拉鲁肽注射液治疗糖尿病肾病对氧化应激损伤和尿白蛋白肌酐比值的影响

Effects of olmesartan medoxomil combined with liraglutide injection on oxidative stress injury and urine albumin-creatinine ratio in diabetic nephropathy

目的分析奥美沙坦酯联合利拉鲁肽注射液治疗糖尿病肾病对氧化应激损伤以及尿白蛋白肌酐比值的影响。方法在2019年7月~2023年2月诊治的糖尿病肾病患者中选取80例作为研究对象,采用随机数字表法将其分为对照组和观察组,各40例。两组均进行基础治疗,对照组在基础治疗基础上使用奥美沙坦酯治疗,观察组在基础治疗的基础上使用奥美沙坦酯联合利拉鲁肽注射液治疗,比较两组治疗效果、氧化应激水平[丙二醛(MDA)、超氧化物歧化酶(SOD)、总抗氧化能力(T-AOC)]、肾功能指标[血肌酐(Scr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)]和尿白蛋白肌酐比值(UACR)。结果观察组治疗有效率90.00%(36/40)高于对照组60.00%(24/40)(P<0.05);两组治疗后MDA水平均降低,且观察组水平较低,两组SOD、T-TOC水平均升高,且观察组水平均较高(P<0.05);两组治疗后Scr、BUN、UAER、UACR水平均降低,且观察组水平较低(P<0.05)。结论奥美沙坦酯联合利拉鲁肽注射液治疗糖尿病肾病具有较好的临床效果,能够减轻患者氧化应激损伤,降低尿白蛋白肌酐比值,改善肾功能。

Objective To analyze the effects of olmesartan medoxomil combined with liraglutide injection on oxidative stress injury and urine albumin-creatinine ratio in diabetic nephropathy.Methods A total of 80 patients with diabetic nephropathy in a hospital from July 2019 to February 2023 were selected as the study objects and divided into the control group and the observation group by random number table method,40 cases in each group.Both groups received conventional treatment,and the control group received olmesartan medoxomil on the basis of conventional treatment;the observation group were treated with olmesartan medoxomil combined with liraglutide injection on the basis of conventional treatment.The therapeutic effect and oxidative stress level[malondialdehyde(MDA),superoxide dismutase(SOD),total antioxidant capacity(total antioxidant capacity,T-AOC)],renal function indicators[serum creatinine(Scr),blood urea nitrogen(BUN),urinary albumin excretion rate(UAER)]and urine albumin-creatinine ratio(UACR)were compared between the two groups.Results The effective rate of the observation group was 90.00%(36/40),which was higher than 60.00%(24/40)of the control group(P<0.05).After treatment,MDA levels were decreased in both groups,and the observation group was lower;SOD and T-TOC levels were increased in both groups,and the observation group were higher(P<0.05);the levels of Scr,BUN,UAER and UACR in both groups were decreased after treatment,and the levels of observation group were lower(P<0.05).Conclusion Olmesartan medoxomil combined with liraglutide injection has a good clinical effect in the treatment of diabetic nephropathy,which can alleviate oxidative stress injury,reduce urine albumin-creatinine ratio and improve renal function.